Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 4/20 | 0.48 |
| ▸ | TSPO | P30536 | 1/20 | 0.48 |
| ▸ | F10 | P00742 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | EDNRB | P24530 | 1/20 | 0.46 |
| ▸ | EDNRA | P25101 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13061912 | 0.92 | KDM4E (0.44) | PLA2G2AF10MAPTHDAC1HDAC6 | |
| SCHEMBL13062047 | 0.90 | P2RX4 (0.55) | PLA2G2AF10HDAC1HDAC6F2 | |
| SCHEMBL13011699 | 0.88 | PLA2G2A (0.42) | PLA2G2AF10MAPTHDAC1F2 | |
| SCHEMBL13634968 | 0.88 | CNR2 (0.41) | PLA2G2AF10MAPTHDAC1HDAC6 | |
| SCHEMBL13061918 | 0.87 | TP53 (0.47) | F10MAPTF2PRSS1POLB | |
| SCHEMBL3767125 | 0.86 | CYP19A1 (0.53) | MAPTHDAC1HDAC6KMT2ACNR2 | |
| SCHEMBL13062129 | 0.85 | HCAR3 (0.55) | TSPOMAPTHDAC1HDAC6KMT2A | |
| SCHEMBL13011250 | 0.84 | MAPT (0.53) | PLA2G2ATSPOF10MAPTHDAC1 | |
| SCHEMBL13011698 | 0.82 | HDAC6 (0.44) | F10HDAC1HDAC6F2PRSS1 | |
| SCHEMBL13011683 | 0.82 | P2RX4 (0.52) | MAPTHDAC1HDAC6POLBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324017-A1 | ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-12-23 | — | — | US | disclosed |
| US-20100324017-A1 | ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324017-A1 | ACYLGUANIDINE DERIVATIVE | HTR5A, GRM5, HTR1E | PLA2G2A 734/4885TSPO 888/4885F10 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.